using the available repertoire of bispecific antibodies for treating multiple myeloma
Published 5 months ago • 74 plays • Length 1:45Download video MP4
Download video MP3
Similar videos
-
1:45
the advent of bispecific antibodies for multiple myeloma
-
1:20
a comparison of bispecific antibodies emerging in multiple myeloma
-
2:06
improving treatment access with off-the-shelf bispecific antibodies in multiple myeloma
-
2:22
outcomes and management of patients with r/r myeloma who progress on bispecific antibodies
-
1:22
risk of infection in patients with multiple myeloma treated with bispecific antibodies
-
4:02
an overview of bispecifics in r/r myeloma and their integration into the treatment landscape
-
1:03
using bispecific antibodies instead of chemotherapy to reach pre-transplant remission in b-all
-
5:00
rouleaux formation | peripheral blood smear examination | hematology | multiple myeloma| esr |
-
6:03
brilliant violet antibody conjugates
-
7:18
response rate on phase 1/2 trial regn5458 (bcmaxcd3 bispecific antibody) for rrmm patients
-
2:50
phase i study of abbv383, a novel bcmaxcd3 bispecific antibody, in r/r multiple myeloma
-
4:26
what are bispecific antibodies?
-
1:37
the promise of elranatamab and other bispecifics in the treatment of myeloma
-
1:33
sequencing and the management of adverse events when administering bispecifics for myeloma
-
2:44
dual-targeting bispecific antibody alnuctamab in r/r multiple myeloma
-
1:23
investigating bispecific antibodies in high-risk smoldering myeloma: the immunoprism platform study
-
0:55
what are bispecific antibodies?
-
6:13
phase i study of forimtamig, a gprc5dxcd3 bispecific antibody, in r/r multiple myeloma
-
57:20
know your myeloma immunotherapy: bispecific antibodies with dr. cesar rodriguez
-
1:56
bfcr4350a: a novel bispecific antibody in r/r myeloma therapy
-
14:00
what are bispecific antibodies?
-
1:36
bispecific antibodies for r/r aml: ongoing clinical trials